02126.HK
JW (Cayman) Therapeutics Co. Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 1.94
−3.72%Aug 27, 2026, 10:02 UTC
JW Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB111.4 million, up 4.7% year-on-year, and net loss narrowed to RMB50.43 million from RMB267.3 million in the prior-year period.
Source: